Loading…
Employees: 2,283
Size Zhejiang Orient Gene Biotech (688298.SS) is a China Health Care company (Medical Specialties) with a market value of $559M, the 3584th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥18.49 on 6 Nov 2026.
Performance Over six months the shares fell 17.2%, against -13.2% for the median peer and -16.4% for the China market (cap-weighted) — 7th lowest of 20 in its peer set.
Growth Revenue grew 17.9% over the last twelve months (peer median +4.2%); the operating margin is -59.9% (peer median 4.4%).
Valuation It trades at 2.0× enterprise value to sales against a peer median of 3.6× (6th cheapest of 18).
Capital Return on invested capital runs 16.0 points below its cost of capital (7.9% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥993M | CN¥945M | CN¥827M | CN¥819M | CN¥8.70B |
| Revenue growth | — | +14% | +1% | -91% | — |
| Gross profit | CN¥448M | CN¥206M | CN¥74.3M | CN¥195M | CN¥4.34B |
| EBITDA | n/a | -CN¥272M | -CN¥535M | -CN¥475M | CN¥1.99B |
| Net income | -CN¥658M | -CN¥574M | -CN¥529M | -CN¥398M | CN¥2.07B |
| Free cash flow | -CN¥384M | -CN¥492M | -CN¥1.24B | -CN¥2.60B | CN¥1.96B |
| Capital expenditure | CN¥269M | CN¥308M | CN¥924M | CN¥996M | CN¥1.05B |
| Total debt | CN¥478M | CN¥397M | CN¥593M | CN¥697M | CN¥600M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688298.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.3% | -4.3% | 10th highest of 20 |
| 6-month return | -17.2% | -13.2% | 7th lowest of 20 |
| Distance from 52-week high | -36.2% | -39.9% | 8th highest of 20 |
| Revenue growth (TTM) | +17.9% | +4.2% | 3rd highest of 20 |
| Operating margin | -59.9% | 4.4% | 2nd lowest of 20 |
| EV / Sales | 2.0× | 3.6× | 6th cheapest of 18 |
| ROIC minus cost of capital | -16.0 pp | -1.3 pp | 4th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Orient Gene Biotech 688298.SS | China | $559M | -17% | +18% | -60% | 2.0× | n/a | n/a |
| Anbio Biotechnology NNNN | United States | $560M | -85% | +10% | 67% | n/a | n/a | n/a |
| MedicalSystem Biotechnology 300439.SZ | China | $556M | -4% | +14% | 2% | 1.7× | 7.4% | -7.8% |
| Sight Sciences SGHT | United States | $555M | -14% | +9% | -33% | 6.2× | n/a | n/a |
| Anteris Technologies Global AVR | United States | $555M | -14% | -10% | -4,738% | 134.2× | n/a | n/a |
| Sahajanand Medical Technologies SMT.NS | India | $566M | n/a | n/a | n/a | n/a | n/a | n/a |
| Myriad Genetics MYGN | United States | $566M | +38% | -3% | -11% | 0.8× | n/a | n/a |
| Guangdong Hybribio Biotech 300639.SZ | China | $568M | -5% | -7% | 4% | 4.5× | 2.7% | -13.2% |
| Nanjing Vishee Medical Technology 688580.SS | China | $550M | -40% | +7% | 24% | 6.0× | 22.3% | +4.2% |
| Medprin Regenerative Medical Technologies 301033.SZ | China | $542M | -3% | +23% | 31% | 8.0× | 6.3% | +24.4% |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $581M | -10% | +6% | 9% | 2.8× | 11.6% | +6.5% |
| Assure Tech (Hangzhou) 688075.SS | China | $538M | -25% | -21% | -7% | n/a | n/a | n/a |
| Zhejiang Starry Pharmaceutical 603520.SS | China | $537M | -32% | +9% | 3% | 2.3× | n/a | n/a |
| medmix MEDX.SW | Switzerland | $537M | +24% | -7% | 6% | 1.5× | 5.0% | +5.0% |
| Tactile Systems Technology TCMD | United States | $583M | +1% | +14% | 9% | 1.5× | 7.8% | +12.0% |
| Jin Medical International ZJYL | United States | $532M | +53% | -14% | 2% | 26.5× | n/a | n/a |
| Nanosonics NAN.AX | Australia | $599M | -13% | +3% | 7% | 3.6× | 34.4% | +6.7% |
| Hangzhou Alltest Biotech 688606.SS | China | $521M | -15% | 0% | 13% | 1.6× | -3.9% | -4.3% |
| Contec Medical Systems 300869.SZ | China | $600M | -23% | -2% | -16% | 6.3× | 17.3% | -19.8% |
| Medistim MEDI.OL | Norway | $601M | +30% | +19% | 29% | 6.8× | -1.8% | +14.5% |
| Guangdong Biolight Meditech 300246.SZ | China | $519M | -23% | +4% | -9% | 3.4× | 14.8% | -4.7% |